Health Condition 1: I21A- Other type of myocardial infarction
Conditions
Interventions
Intervention1: Ticagrelor SR Tablets 180 mg: One tablet once a day orally in the morning every day for 168 days (24 weeks)
Intervention2: Ticagrelor SR Tablets 120 mg: One tablet once a day orally in
Sponsors
Synokem Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female subjects aged between 40 and 75 years (both inclusive). 2. Subjects who are currently on the treatment of Ticagrelor Tablets 90 mg twice daily or 60 mg twice daily from at least 3 months with the history of myocardial infarction. 3. Subjects with ability to understand and provide written informed consent form, which must have been obtained prior to screening. 4. Subjects willing to comply with the protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Subjects who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start. 2. Subjects who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start. 3. Subjects with history of multi vessel coronary artery disease. 4. Subjects with history of bleeding disorders. 5. Subjects who need chronic oral anti-coagulant therapy or chronic low-molecular weight heparin. 6. Subjects with a history of ischemic stroke. 7. Subjects with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years. 8. Subjects with a history of bleeding from the gastrointestinal tract (e.g., esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days. 9. Subjects considered to be at risk of bradycardic events unless already treated with a permanent pacemaker. 10. Subjects who have had open heart surgery within the past 5 years, unless the person had a myocardial infarction after the surgery. 11. Subjects with clinically significant impaired hepatic function. [SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 1.5X the UNL]. 12. Subjects with kidney failure requiring dialysis. 13. Subjects with known clinically important thrombocytopenia. 14. Female subjects who are pregnant or lactating or planning to become pregnant during the study period. 15. Females who are not ready to use acceptable contraceptive methods during the course of study. 16. Concurrent participation in another clinical trial or any investigational therapy within 90 days prior to signing informed consent. 17. Subjects with history of HIV and or Hepatitis B and or Hepatitis C. 18. Suspected inability or unwillingness to comply with the study procedures. 19. Subjects with clinically significant disorder that, in the opinion of the investigator, would result in jeopardizing patient’s safety and efficacy of the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Any event after randomization from the composite of cardiovascular death, non-fatal MI, or non-fatal stroke.Timepoint: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 18 and Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| The assessment of safety of subjects [comparison of incidence of treatment emergent adverse event (TEAE)].Timepoint: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 18 and Week 24 | — |
Countries
India
Contacts
Public ContactRahul Vij
Synokem Pharmaceuticals Ltd.
Outcome results
None listed